Neal Muni - 19 May 2022 Form 3/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc.

Role: Executive Vice President and Chief Operating Officer. Exhibit 24 Power of Attorney filed herewith.
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol: CMRA on OTC
Transactions as of: 19 May 2022
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 14 Feb 2023, 16:15:59 UTC
Date Of Original Report: 20 May 2022
Next filing: 11 Aug 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CMRA	Stock Option (Right to Buy)							19 May 2022	Common Stock	208,198	$0.5900	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3/A is being filed to correct information previously disclosed on the original Form 3 filed by the reporting person on May 20, 2022, including the Exercise Price, Amount or Number of Shares and vesting schedule of the stock option grant. This Form 3/A also includes the reporting person's power-of-attorney.
F2	This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on September 16, 2021. 25% of the option vests or vested on the one year anniversary of the grant date and in equal monthly installments thereafter for 36 months.

Remarks:

Executive Vice President and Chief Operating Officer. Exhibit 24 Power of Attorney filed herewith.